- Home
- SONM vs KZIA Comparison
SONM vs KZIA Comparison
Compare SONM & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$3.20
HOLD
Current Price
$7.16
Company Overview
Basic Information| Metric | SONM | KZIA |
|---|---|---|
| Founded | 1999 | 1994 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.5M | 93.2M |
| IPO Year | 2019 | 2002 |
Fundamental Metrics
Financial Performance| Metric | SONM | KZIA |
|---|---|---|
| Price | $3.20 | $7.16 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $17.67 |
| AVG Volume (30 Days) | 18.8K | ★ 129.5K |
| Earning Date | 05-11-2026 | 11-07-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $58,298,000.00 | N/A |
| Revenue This Year | $127.68 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.52 | $0.64 |
| 52 Week High | $12.30 | $17.40 |
Technical Indicators
Market Signals| Indicator | SONM | KZIA |
|---|---|---|
| Relative Strength Index (RSI) | 40.43 | 46.86 |
| Support Level | $0.64 | $5.64 |
| Resistance Level | $7.08 | $8.05 |
| Average True Range (ATR) | 0.50 | 0.80 |
| MACD | -0.09 | -0.14 |
| Stochastic Oscillator | 41.46 | 18.12 |
Price Performance
Historical Comparison SONM
KZIA
About SONM Sonim Technologies Inc.
DNA X Inc operates a digital asset management platform.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.